Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners
Linkedbio Partnering: Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing
Linkedbio Analysis: Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients
Lingmed Newsletter Nov 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Innovative type 2 diabetes sustained-release project from US
Lingmed asset recommendation 2:Migraine Inhalation Project from EU
The Oct 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Oct 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Oct 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Innovative oral preparation project for Age-related Macular Degeneration
Lingmed asset recommendation 2:Innovative respiratory disease project from EU
Lingmed monthly webinar Nov 2023: Research progress in the pathogenesis and treatment of depression
The Sep 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Sep 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Sep 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Long-acting Pulmonary Arterial Hypertension Program from EU
Lingmed asset recommendation 2:Long-acting Preloaded Prostate Cancer program from EU
Lingmed monthly webinar Oct 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The Aug 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.344
European Long-Term Pulmonary Arterial Hypertension Program seeks global partnering
Global and China Pulmonary Hypertension Epidemiology
Global Pulmonary Arterial Hypertension Drug Ranking
Treatment of Pulmonary Arterial Hypertension in China
Lingmed innovative asset recommendation –Pulmonary Arterial Hypertension
Lingmed asset recommendation No.343
European Long-acting Preloaded Prostate Cancer program seeks global partnering - LMP1855
Global and China Prostate Cancer Epidemiology
Global Prostate Cancer Drug Ranking
Treatment of Prostate Cancer in China
Lingmed innovative asset recommendation – Prostate Cancer program
Lingmed Newsletter Aug 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria
Lingmed asset recommendation 2:Innovative Chronic Kidney Disease program
Lingmed monthly webinar Sep 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The 12th Pharma - Biotech Product and Company Valuation Register
The July 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The July 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.341
Innovative Chronic Kidney Disease program seeks a global partner
Global and China Chronic Kidney Disease Epidemiology
Global Chronic Kidney Disease Drug Ranking
Treatment of Chronic Kidney Disease in China
Lingmed innovative asset recommendation – Chronic Kidney Disease project
Lingmed asset recommendation No.340
Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria?
Global and Chinese Epidemiology of Chronic Spontaneous Urticaria
Global and Chinese Urticaria Drug Ranking
Treatment of Chronic Spontaneous Urticaria in China
Lingmed innovative asset recommendation – Chronic Spontaneous Urticaria Program
Lingmed asset recommendation No.338
China's rising stars of innovation - portable inhalation device for pulmonary hypertension - Patent global licensing opportunity LMP1853
Medical NO gas therapy has wide application potential
Integrating more than 60 patents to establish a solid NO generation molecular technology platform
Potential indications and product forms
Portable nitric oxide inhalation therapy device
Product features
The main uses of the LMP1853 portable inhaled nitric oxide therapy device
Cooperation models
Lingmed Newsletter July 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Innovative U.S. Anesthesia Reversal Agent program
Lingmed asset recommendation 2:Oversea topical skin disease innovation
Lingmed monthly webinar Aug 2023: Development progress of new drug development for skin diseases Register
The 12th Pharma - Biotech Product and Company Valuation Register
The Jun 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jun 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.336
Oversea topical skin disease innovations
Global and Chinese Acne Epidemiology
Global and Chinese Acne Drug List
Chinese acne treatment
Lingmed innovative asset recommendation – Skin Disease Program
Lingmed asset recommendation No.336
Innovative U.S. Anesthesia Reversal Agent program seeks partnering into China market
Global Epidemiology of Delayed Awakening from Anesthesia
Global & Chinese Delayed Awakening from Anesthesia Drug Ranking
Chinese Guidelines for Treatment of Delayed Awakening from Anesthesia
Lingmed innovative asset recommendation – Anesthesia Reversal Agent Program
Lingmed Newsletter June 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:New breakthrough in innovative target for rare blood diseases
Lingmed asset recommendation 2:Overseas Primary Sclerosing Cholangitis program
Lingmed monthly webinar Jul 2023: Chronic Pain Market Development Potential and Market Size Register
The 12th Pharma - Biotech Product and Company Valuation Register
The May 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.334
Overseas primary sclerosing cholangitis program seeks partnering into China market
Global and Chinese PSC Epidemiology
Global & Chinese PSC Drug Ranking
Chinese guidelines for diagnosis and treatment of PSC
Lingmed innovative asset recommendation – Primary Sclerosing Cholangitis Program
Lingmed asset recommendation No.333
New breakthrough in innovative target for rare blood diseases - LMP1421
Global PNH Epidemiology
Global & Chinese PNH Drug Ranking
Chinese guidelines for diagnosis and treatment of PNH
Lingmed innovative asset recommendation – PHN Program
Lingmed Newsletter May 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Overseas First-Line Therapy Program for Pancreatic Cancer
Lingmed asset recommendation 2:U.S. Innovative Oncology Program
Lingmed monthly webinar Jun 2023: Prospects for drug development of heterologous antibodies Register
The Apr 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.331
Oncology innovation from US biotech seeks partnering into China market
Global epidemiology of AML/ALL, DLBCL, MM and other tumors
Global & Chinese AML/ALL Drug Ranking
China AML/ALL diagnosis and treatment guidelines
Lingmed innovative asset recommendation – Multi-tumor Indication Program
Lingmed asset recommendation No.328
Overseas First-Line Therapy Program for Pancreatic Cancer Seeks Chinese Collaboration
Global & Chinese Pancreatic Cancer Epidemiology
Global Pancreatic Cancer Drug Ranking
China Pancreatic Cancer Treatment Guidelines (2022)
Lingmed innovative asset recommendation – Pancreatic Cancer and Pulmonary Fibrosis Program
Lingmed Newsletter April 2023
In this month summary, Lingmed recommends
Lingmed asset recommendation 1:Phase III Tenosynovial Giant Cell Tumor Program from EU
Lingmed asset recommendation 2:U.S. Innovative Respiratory Infection Program
Lingmed monthly webinar May 2023: R&D pattern analysis of novel drug delivery systems Register
The Mar 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.329
U.S. Innovative Respiratory Infection Program Seeks Chinese Collaboration
Company Profile
Respiratory Infection Program LMP1857 Introduction
LMP1857 potential applications
LMP1857 patent status
LMP1857 Cooperation Opportunities
Lingmed asset recommendation No.327
European Phase III Tenosynovial Giant Cell Tumor Program Seeks Chinese Collaboration
Global & Chinese Epidemiology of Tenosynovial Giant Cell Tumor
Global Tenosynovial Giant Cell Tumor Drug Ranking
Guidelines for Diagnosis and Treatment of Giant Cell Tumor of the Tendon Sheath in China
Lingmed innovative asset recommendation – Tenosynovial giant cell tumor program
If you are interested in Lingmed historical achieved reports, please click here
Confirm your details on form below to download this report